RxDoctor Payments Data

Stuart Cooper, MD

Internal Medicine · Lexington, SCNPI 1942223086

Payments from drug & device makers

$5,221in general payments, 2019–2025

Across 313 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$656
  • AstraZeneca$572
  • Lilly USA, LLC$416
  • Pfizer$377
  • Amgen$351
  • AbbVie$308
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$5,221100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,221 in reported general payments places this provider in the 85th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$158,713
Medicare patients
3,918
Services billed
7,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide134$196,199
EliquisApixaban160$115,013
JardianceEmpagliflozin129$109,061
JanuviaSitagliptin Phosphate83$58,822
TrulicityDulaglutide43$57,319
XifaxanRifaximin17$50,847
MyrbetriqMirabegron75$49,189
Tresiba Flextouch U-200Insulin Degludec36$40,212
XareltoRivaroxaban49$39,882
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$38,937
Tresiba Flextouch U-100Insulin Degludec45$34,167
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr53$33,439
RybelsusSemaglutide20$32,018
LinzessLinaclotide44$30,768
FarxigaDapagliflozin Propanediol32$30,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$656$228,217154 claims
PfizerEliquis, Lyrica$377$121,970172 claims
Boehringer IngelheimJardiance, Combivent Respimat$110$120,237142 claims
MerckJanuvia, Belsomra$17$74,322119 claims
GSKTrelegy Ellipta, Anoro Ellipta$118$72,37696 claims
Lilly USA, LLCTrulicity, Mounjaro$416$70,59455 claims
AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere, Symbicort$572$60,56495 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$229$50,84717 claims
Astellas Pharma US IncMyrbetriq$71$49,18975 claims
Johnson & JohnsonXarelto$69$39,88249 claims
AbbVieLinzess, Creon$308$37,92360 claims
Sumitomo Pharma America, Inc.Gemtesa$65$15,65427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Lexington

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →